Response‐adapted therapy for the treatment of children with newly diagnosed high risk Hodgkin lymphoma (AHOD0831): a report from the Children’s Oncology Group-Reference-Cited by-同舟云学术

Response‐adapted therapy for the treatment of children with newly diagnosed high risk Hodgkin lymphoma (AHOD0831): a report from the Children’s Oncology Group

Published:2019-06-10 Issue:1 Volume:187 Page:39-48
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Kelly Kara M.¹^ORCID,Cole Peter D.²,Pei Qinglin³,Bush Rizvan⁴,Roberts Kenneth B.⁵,Hodgson David C.⁶,McCarten Kathleen M.⁷,Cho Steve Y.⁸,Schwartz Cindy⁹

Affiliation:

1. Department of Pediatric Oncology, Roswell Park Comprehensive Cancer Center Department of Pediatrics University at Buffalo Jacobs School of Medicine and Biomedical Sciences Buffalo NYUSA

2. Division of Pediatric Hematology/Oncology Robert Wood Johnson Medical School, Rutgers Cancer Institute of New Jersey New Brunswick NJ USA

3. Department of Biostatistics University of Florida, Children’s Oncology Group, Statistics and Data Center Gainesville FLUSA

4. Children’s Oncology Group Statistics and Data Center Monrovia CA USA

5. Department of Therapeutic Radiology Yale University School of Medicine, Yale‐New Haven Hospital New Haven CT USA

6. Department of Radiation Oncology University of Toronto, Princess Margaret Hospital Toronto Ontario Canada

7. Department of Diagnostic Imaging, Warren Alpert Medical School Brown University Providence RI USA

8. Department of Radiology University of Wisconsin School of Medicine and Public Health, University of Wisconsin Carbone Cancer Center Madison WI USA

9. Division of Pediatric Hematology, Oncology and BMT Medical College of Wisconsin Milwaukee WI USA

Funder

St. Baldrick's Foundation

National Cancer Institute

National Institutes of Health

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.16014

Reference22 articles.

1. Eight Cycles of Escalated-Dose BEACOPP Compared With Four Cycles of Escalated-Dose BEACOPP Followed by Four Cycles of Baseline-Dose BEACOPP With or Without Radiotherapy in Patients With Advanced-Stage Hodgkin's Lymphoma: Final Analysis of the HD12 Trial of the German Hodgkin Study Group

2. PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group

3. PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 study

4. Revised Response Criteria for Malignant Lymphoma

5. Dose-Intensive Response-Based Chemotherapy and Radiation Therapy for Children and Adolescents With Newly Diagnosed Intermediate-Risk Hodgkin Lymphoma: A Report From the Children's Oncology Group Study AHOD0031

Cited by 44 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment of high‐risk Hodgkin lymphoma with a modified Stanford V regimen in the AHOPCA: Substituting chemotherapy agents and hampered outcomes;Pediatric Blood & Cancer;2023-12-05

2. Classic Hodgkin Lymphoma in Adolescents and Young Adults;Journal of Clinical Oncology;2023-11-20

3. Performance of the FACT-GOG-Ntx to assess chemotherapy-induced peripheral neuropathy (CIPN) in pediatric high risk Hodgkin lymphoma: report from the Children’s Oncology Group AHOD 1331 study;Journal of Patient-Reported Outcomes;2023-11-10

4. Outcome and prognostic factors of pediatric patients with Hodgkin lymphoma: a single-center experience;Journal of the Egyptian National Cancer Institute;2023-09-11

5. Importance of Central Imaging Review in a Pediatric Hodgkin Lymphoma Trial Using Positron Emission Tomography Response Adapted Radiation Therapy;International Journal of Radiation Oncology*Biology*Physics;2023-08